← Leaderboards
Ronald Levy
Stanford University
$27,846,042
Attributed
$33,517,040
Total exposure
27
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$52,979,838 · 28
By mechanism
P01$23,494,821 · 7
R01$9,905,620 · 5
R35$6,114,992 · 1
R37$4,542,274 · 1
U01$3,146,603 · 1
T32$2,695,379 · 1
Top collaborators
- Arash Ash Alizadeh5 shared
- Mark M Davis5 shared
- Katherine W Ferrara5 shared
- Robert M. Waymouth5 shared
- Paul Wender5 shared
- Joshua E Elias4 shared
Most similar at Stanford University
Same institution · by research overlap
- Maximilian Diehn$12,346,945
- Edgar G. Engleman$35,389,843
- Katherine W Ferrara$45,937,231
- David Matthew Kurtz$956,520
- Brian Sworder$564,903
Others in their field
Top investigators on “Lymphoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$171,980,034
- Richard L Schilsky · University Of Chicago$120,036,663
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$113,682,224
- Ronald T Mitsuyasu · University Of California Los Angeles$103,553,444
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Charles A Coltman · Southwest Oncology Group$55,198,633
Research focus
LymphomaCellsTumorMalignant NeoplasmsImmune SystemClinical TrialsNeoplastic CellImmunotherapyClinical ResearchImmune ResponseResponseT-LymphocyteVaccinationBaseTissuesMonoclonal AntibodiesNeoplasm /Cancer VaccineMonitorHuman SubjectImmuneSignal PathwayDiagnosisClinicPrograms
Grant awards (122)
Imaging Modulation of Immune Phenotype$653,804
R01 · FY2025 · CA
Hematologic Malignancies$169,872
P30 · FY2025 · CA · contact PI
Imaging Modulation of Immune Phenotype$621,116
R01 · FY2024 · CA
New Materials to Deliver mRNA: Applications in Cancer Immunotherapy$525,103
R01 · FY2024 · CA
Hematologic Malignancies$55,542
P30 · FY2024 · CA · contact PI
Imaging Modulation of Immune Phenotype$641,412
R01 · FY2023 · CA
New Materials to Deliver mRNA: Applications in Cancer Immunotherapy$514,997
R01 · FY2023 · CA
Hematologic Malignancies$55,542
P30 · FY2023 · CA · contact PI
Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host$820,359
R35 · FY2022 · CA · contact PI
Imaging Modulation of Immune Phenotype$641,412
R01 · FY2022 · CA
New Materials to Deliver mRNA: Applications in Cancer Immunotherapy$512,443
R01 · FY2022 · CA
Hematologic Malignancies$55,542
P30 · FY2022 · CA · contact PI
Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host$849,297
R35 · FY2021 · CA · contact PI
Imaging Modulation of Immune Phenotype$669,526
R01 · FY2021 · CA
New Materials to Deliver mRNA: Applications in Cancer Immunotherapy$522,472
R01 · FY2021 · CA
Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host$863,419
R35 · FY2020 · CA · contact PI
New Materials to Deliver mRNA: Applications in Cancer Immunotherapy$546,613
R01 · FY2020 · CA
Lymphoma & Leukemia Research Program (Project-007)$43,892
P30 · FY2020 · CA · contact PI
Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host$853,049
R35 · FY2019 · CA · contact PI
Modeling the Molecular Determinants of Induced Anti-Tumor Immune Responses in Mantle Cell Lymphoma$604,097
U01 · FY2019 · CA
Lymphoma & Leukemia Research Program (Project-007)$43,761
P30 · FY2019 · CA · contact PI
Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host$894,960
R35 · FY2018 · CA · contact PI
Modeling the Molecular Determinants of Induced Anti-Tumor Immune Responses in Mantle Cell Lymphoma$632,932
U01 · FY2018 · CA
Lymphoma & Leukemia Research Program (Project-007)$43,896
P30 · FY2018 · CA · contact PI
Lymphoma & Leukemia Research Program (Project-007)$11,296
P30 · FY2018 · CA · contact PI
Lymphoma & Leukemia Research Program (Project-007)$7,796
P30 · FY2018 · CA · contact PI
Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host$909,837
R35 · FY2017 · CA · contact PI
Modeling the Molecular Determinants of Induced Anti-Tumor Immune Responses in Mantle Cell Lymphoma$643,804
U01 · FY2017 · CA
Auto-lmmunotransplantation for Lymphoma$199,532
P01 · FY2017 · CA · contact PI
Lymphoma & Leukemia Research Program (Project-007)$32,997
P30 · FY2017 · CA · contact PI
Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host$924,071
R35 · FY2016 · CA · contact PI
Modeling the Molecular Determinants of Induced Anti-Tumor Immune Responses in Mantle Cell Lymphoma$638,806
U01 · FY2016 · CA
Auto-lmmunotransplantation for Lymphoma$199,530
P01 · FY2016 · CA · contact PI
Lymphoma & Leukemia Research Program (Project-007)$36,782
P30 · FY2016 · CA · contact PI
Modeling the Molecular Determinants of Induced Anti-Tumor Immune Responses in Mantle Cell Lymphoma$626,964
U01 · FY2015 · CA
Genetic Basis of Signaling Heterogeneity in Human Follicular Lymphoma$486,627
R01 · FY2015 · CA · contact PI
Therapeutic In Situ Vaccination for Human Lymphoma$311,682
R01 · FY2015 · CA · contact PI
Auto-lmmunotransplantation for Lymphoma$199,530
P01 · FY2015 · CA · contact PI
Genetic Basis of Signaling Heterogeneity in Human Follicular Lymphoma$473,177
R01 · FY2014 · CA · contact PI
Therapeutic In Situ Vaccination for Human Lymphoma$311,682
R01 · FY2014 · CA · contact PI
Auto-lmmunotransplantation for Lymphoma$193,544
P01 · FY2014 · CA · contact PI
MODELING THE ROLE OF PROGRESSION IN FOLLICULAR LYMPHOMA$145,689
U54 · FY2014 · CA · contact PI
Lymphoma$52,923
P30 · FY2014 · CA · contact PI
Genetic Basis of Signaling Heterogeneity in Human Follicular Lymphoma$459,677
R01 · FY2013 · CA · contact PI
Enhancing tumor-targeted antibody therapy with a second NK activating antibody.$244,457
R01 · FY2013 · CA · contact PI
Auto-lmmunotransplantation for Lymphoma$199,529
P01 · FY2013 · CA · contact PI
MODELING THE ROLE OF PROGRESSION IN FOLLICULAR LYMPHOMA$170,140
U54 · FY2013 · CA · contact PI
Lymphoma$14,100
P30 · FY2013 · CA · contact PI
Genetic Basis of Signaling Heterogeneity in Human Follicular Lymphoma$490,247
R01 · FY2012 · CA · contact PI
Enhancing tumor-targeted antibody therapy with a second NK activating antibody.$259,967
R01 · FY2012 · CA · contact PI
MODELING THE ROLE OF PROGRESSION IN FOLLICULAR LYMPHOMA$197,230
U54 · FY2012 · CA · contact PI
Lymphoma$15,065
P30 · FY2012 · CA · contact PI
Genetic Basis of Signaling Heterogeneity in Human Follicular Lymphoma$491,503
R01 · FY2011 · CA · contact PI
Enhancing tumor-targeted antibody therapy with a second NK activating antibody.$259,878
R01 · FY2011 · CA · contact PI
MODELING THE ROLE OF PROGRESSION IN FOLLICULAR LYMPHOMA$194,598
U54 · FY2011 · CA · contact PI
Lymphoma$15,416
P30 · FY2011 · CA · contact PI
Clinical and Laboratory Studies of Malignant Lymphomas$1,745,511
P01 · FY2010 · CA · contact PI
In Situ Vaccination for Lymphoma by Intratumoral Injection of Immunostimulatory$415,685
P01 · FY2010 · CA · contact PI
Enhancing tumor-targeted antibody therapy with a second NK activating antibody.$267,825
R01 · FY2010 · CA · contact PI
MODELING THE ROLE OF PROGRESSION IN FOLLICULAR LYMPHOMA$211,177
U54 · FY2010 · CA · contact PI
Lymphoma$17,352
P30 · FY2010 · CA · contact PI
Clinical and Laboratory Studies of Malignant Lymphomas$1,717,701
P01 · FY2009 · CA · contact PI
In Situ Vaccination for Lymphoma by Intratumoral Injection of Immunostimulatory$409,943
P01 · FY2009 · CA · contact PI
Clinical and Laboratory Studies of Malignant Lymphomas$1,681,253
P01 · FY2008 · CA · contact PI
In Situ Vaccination for Lymphoma by Intratumoral Injection of Immunostimulatory$399,138
P01 · FY2008 · CA · contact PI
Clinical and Laboratory Studies of Malignant Lymphomas$1,662,201
P01 · FY2007 · CA · contact PI
Anti-Idiotype Therapy of Human B Cell Malignancy$594,988
R37 · FY2007 · CA · contact PI
In Situ Vaccination for Lymphoma by Intratumoral Injection of Immunostimulatory$398,780
P01 · FY2007 · CA · contact PI
TRAINING PROGRAM IN INVESTIGATIVE ONCOLOGY$360,259
T32 · FY2007 · CA · contact PI
Clinical and Laboratory Studies of Malignant Lymphomas$1,680,204
P01 · FY2006 · CA · contact PI
Anti-Idiotype Therapy of Human B Cell Malignancy$597,135
R37 · FY2006 · CA · contact PI
TRAINING PROGRAM IN INVESTIGATIVE ONCOLOGY$360,363
T32 · FY2006 · CA · contact PI
Therapeutic vaccination for lymphoma w dendritic cells$327,507
P01 · FY2006 · HL · contact PI
In Situ Vaccination for Lymphoma Intratumoral Injection$243,491
P01 · FY2006 · CA · contact PI
Administration and Research Coordination$56,517
P01 · FY2006 · CA · contact PI
Anti-Idiotype Therapy of Human B Cell Malignancy$595,628
R37 · FY2005 · CA
TRAINING PROGRAM IN INVESTIGATIVE ONCOLOGY$360,271
T32 · FY2005 · CA
CLINICAL AND LABORATORY STUDIES OF MALIGNANT LYMPHOMAS$2,471,663
P01 · FY2004 · CA
Anti-Idiotype Therapy of Human B Cell Malignancy$578,610
R37 · FY2004 · CA
TRAINING PROGRAM IN INVESTIGATIVE ONCOLOGY$360,363
T32 · FY2004 · CA
CLINICAL AND LABORATORY STUDIES OF MALIGNANT LYMPHOMAS$2,139,983
P01 · FY2003 · CA
Anti-Idiotype Therapy of Human B Cell Malignancy$560,403
R37 · FY2003 · CA
TRAINING PROGRAM IN INVESTIGATIVE ONCOLOGY$356,998
T32 · FY2003 · CA
Clinical and Laboratory Studies of Malignant Lymphomas$262,931
P01 · FY2003 · CA
CLINICAL AND LABORATORY STUDIES OF MALIGNANT LYMPHOMAS$2,087,820
P01 · FY2002 · CA
ANTIIDIOTYPE THERAPY OF HUMAN B CELL MALIGNANCY$552,663
R37 · FY2002 · CA
TRAINING PROGRAM IN INVESTIGATIVE ONCOLOGY$328,604
T32 · FY2002 · CA
Therapeutic vaccination for lymphoma w dendritic cells$189,283
P01 · FY2002 · HL
TCR vaccines for T cell malignancy$0
P01 · FY2002 · CA
IDIOTYPE VACCINATION AFTER ALLOGENEIC TRANSPLANTATION$0
P01 · FY2002 · CA
CLINICAL AND LABORATORY STUDIES OF MALIGNANT LYMPHOMAS$2,032,209
P01 · FY2001 · CA
ANTIIDIOTYPE THERAPY OF HUMAN B CELL MALIGNANCY$538,364
R37 · FY2001 · CA
TRAINING PROGRAM IN INVESTIGATIVE ONCOLOGY$287,468
T32 · FY2001 · CA
IDIOTYPE PULSED DENDRITIC CELLS FOR LYMPHOMA$189,283
P01 · FY2001 · HL
IDIOTYPE VACCINATION WITH MURAMYL DIPEPTIDE IN LYMPHOMA$134,676
M01 · FY2001 · RR
VACCINE THERAPY FOR B CELL LYMPHOMA--PLASMID DNA IDIOTYP$134,676
M01 · FY2001 · RR
IDIOTYPE VACCINATION AFTER BMT FOR B CELL MALIGNANCIES$134,676
M01 · FY2001 · RR
VACCINATION WITH AUTOLOGOUS DENDRITIC CELLS WITH B CELL LYMPHOMA$134,676
M01 · FY2001 · RR
IDIOTYPE VACCINES FOR TREATMENT OF LOW GRADE B CELL LYMPHOMA$134,676
M01 · FY2001 · RR
SUPER COMPUTER SIMULATIONS OF LIQUIDS &PROTEINS$12,855
P41 · FY2001 · RR
VACCINATION WITH AUTOLOGOUS DENDRITIC CELLS WITH B CELL LYMPHOMA$0
M01 · FY2001 · RR
IDIOTYPE VACCINATION AFTER BONE MARROW TRANSPLANTATION FOR B CELL MALIGNANCIES$0
P01 · FY2001 · CA
TCR vaccines for T cell malignancy$0
P01 · FY2001 · CA
IDIOTYPE VACCINATION WITH MURAMYL DIPEPTIDE IN LYMPHOMA$0
M01 · FY2001 · RR
IDIOTYPE VACCINES FOR TREATMENT OF LOW GRADE B CELL LYMPHOMA$0
M01 · FY2001 · RR
VACCINE THERAPY FOR B CELL LYMPHOMA--PLASMID DNA IDIOTYP$0
M01 · FY2001 · RR
IDIOTYPE VACCINATION AFTER BMT FOR B CELL MALIGNANCIES$0
M01 · FY2001 · RR
CLINICAL AND LABORATORY STUDIES OF MALIGNANT LYMPHOMAS$1,981,322
P01 · FY2000 · CA
GM/CSF FUSION PROTEINS &DENDRITIC CELLS AS TUMOR VACCIN$777,182
U19 · FY2000 · CA
ANTIIDIOTYPE THERAPY OF HUMAN B CELL MALIGNANCY$524,483
R37 · FY2000 · CA
TRAINING PROGRAM IN INVESTIGATIVE ONCOLOGY$281,053
T32 · FY2000 · CA
IDIOTYPE VACCINATION AFTER BONE MARROW TRANSPLANTATION FOR B CELL MALIGNANCIES$221,448
P01 · FY2000 · CA
IDIOTYPE PULSED DENDRITIC CELLS FOR LYMPHOMA$189,283
P01 · FY2000 · HL
SUPER COMPUTER SIMULATIONS OF LIQUIDS &PROTEINS$24,318
P41 · FY2000 · RR
VACCINATION WITH AUTOLOGOUS DENDRITIC CELLS WITH B CELL LYMPHOMA$602
M01 · FY2000 · RR
IDIOTYPE VACCINATION AFTER BMT FOR B CELL MALIGNANCIES$602
M01 · FY2000 · RR
DOSING OF IDEC-C2B8 WITH LOW GRADE OR FOLLICULAR B CELL LYMPHOMA$602
M01 · FY2000 · RR
IDIOTYPE VACCINATION WITH MURAMYL DIPEPTIDE IN LYMPHOMA$0
M01 · FY2000 · RR
IDIOTYPE VACCINES FOR TREATMENT OF LOW GRADE B CELL LYMPHOMA$0
M01 · FY2000 · RR
VACCINE THERAPY FOR B CELL LYMPHOMA--PLASMID DNA IDIOTYP$0
M01 · FY2000 · RR
TCR vaccines for T cell malignancy$0
P01 · FY2000 · CA
IDIOTYPE VACCINATION AFTER BONE MARROW TRANSPLANTATION FOR B CELL MALIGNANCIES$0
P01 · FY2000 · CA